News Sentiment

CRMD sentiment intelligence

CorMedix Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.67 Week of 19 Jun 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

75/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-0.8% over one week, +8.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Why (CRMD) Price Action Is Critical for Tactical Trading

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 75/100 classification
One-week reaction -0.8% Price digesting
Trend fit Trend inactive 8.6% over four weeks
Fair value 14.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 24
Neutral 24
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 18
Stock Titan 7
simplywall.st 7
TradingKey 4
Simply Wall Street 3
Stocktwits 3
TradingView 3
MarketBeat 2

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 23
Deals and strategy 4
Analyst action 2
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Stock Traders Daily Direct company coverage

Why (CRMD) Price Action Is Critical for Tactical Trading

This article analyzes Cormedix Inc. (CRMD) using AI models, highlighting weak near-term sentiment but strong mid-term indicators within a broader long-term weak bias. It discusses institutional trading strategies, including long, breakout, and short positions, and provides multi-

Tone
Neutral 50/100
Event
Market update
Published
21 Jun 2026 00:41
Source
Stock Traders Daily
Simply Wall Street Direct company coverage

Raised 2026 Guidance and DefenCath Momentum Might Change The Case For Investing In CorMedix (CRMD)

CorMedix reported strong Q1 2026 results driven by DefenCath and raised its full-year guidance, emphasizing continued business momentum despite the upcoming expiration of temporary TDAPA reimbursement. The company's investment narrative hinges on DefenCath's sustained performance

Tone
Positive 73/100
Event
Earnings
Published
18 Jun 2026 05:09
Source
Simply Wall Street
Simply Wall Street Direct company coverage

CRMD: Raised 2026 Guidance And Late-Stage Pipeline Progress Will Support Undervalued Shares

CorMedix (CRMD) reported Q1 2026 results, showing significant revenue contributions from DefenCath and raising full-year 2026 net revenue guidance to $325 million to $345 million. The company is also progressing with its REZZAYO pipeline, targeting an sNDA submission to the FDA i

Tone
Positive 72/100
Event
Earnings
Published
17 Jun 2026 16:40
Source
Simply Wall Street
TradingKey Direct company coverage

CorMedix Inc (CRMD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of CorMedix Inc (CRMD), listing major shareholders and their proportional holdings, such as Deep Track Capital LP and BlackRock. It also categorizes shareholders by type and provides institutional shareholding data over several quart

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 14:11
Source
TradingKey
TradingKey Direct company coverage

CorMedix Inc (CRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for CorMedix Inc (CRMD), highlighting that relevant data for business segments and profit contribution have not yet been disclosed by the company. It does, however, indicate a significant portion of revenue, totaling $311.

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 13:11
Source
TradingKey
TradingKey Direct company coverage

CorMedix Inc (CRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates

CorMedix Inc (CRMD) has an earnings forecast score of 8.29, ranking 44th in the Pharmaceuticals industry, with an average analyst price target of $20.00. Based on 6 analyst ratings, the company generally receives a "Buy" recommendation. The article also provides details on expect

Tone
Positive 71/100
Event
Earnings
Published
17 Jun 2026 12:11
Source
TradingKey
TradingKey Direct company coverage

CorMedix Inc (CRMD) Financial Health: Profitability & Balance Sheet Analysis

CorMedix Inc (CRMD) has a robust financial score of 8.94, ranking 25th out of 157 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 226.05% to $127.43 million an

Tone
Positive 77/100
Event
Earnings
Published
16 Jun 2026 16:40
Source
TradingKey
Market source Direct company coverage

The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why

CorMedix (CRMD) reported strong Q1 2026 results, with DefenCath driving revenue and management raising guidance for the full year. The company also highlighted progress for REZZAYO, strengthening the investment case despite potential reimbursement pressures for DefenCath after it

Tone
Positive 73/100
Event
Earnings
Published
16 Jun 2026 05:12
Source
Market source
Stock Titan Direct company coverage

CorMedix (CRMD) holder reports 4.62M shares, 5.89% stake

SHAIBATALHAMD AYMEN ABDALKADER has filed an amended Schedule 13G/A, disclosing beneficial ownership of 4,618,511 shares of CorMedix Inc. (CRMD) common stock, which represents a 5.89% stake in the company. The filing indicates the holder has sole voting and dispositive power over

Tone
Neutral 50/100
Event
Deals and strategy
Published
12 Jun 2026 17:38
Source
Stock Titan
Stock Titan Direct company coverage

CorMedix (CRMD): Investor reports 4.62M shares, 5.89% stake

A Schedule 13G/A filing indicates that investor Aymen Abdalkader Shaibata has reported beneficial ownership of 4,618,511 shares of CorMedix Inc. (CRMD) common stock, representing a 5.89% stake. The filing, signed on June 12, 2026, denotes that Shaibata holds sole voting and dispo

Tone
Neutral 50/100
Event
Deals and strategy
Published
12 Jun 2026 16:38
Source
Stock Titan
Insider Monkey Direct company coverage

5 Most Profitable Small Cap Stocks to Buy

This article highlights CorMedix Inc. (NASDAQ:CRMD) as one of the most profitable small-cap stocks, detailing its Q1 2026 financial performance, including significant revenue and net income growth driven by DefenCath and the acquired Melinta portfolio. The company has raised its

Tone
Positive 75/100
Event
Earnings
Published
11 Jun 2026 19:50
Source
Insider Monkey
Investing.com UK Direct company coverage

Federal appeals court upholds CorMedix patent win over Nexus

A federal appeals court has affirmed a lower court ruling in favor of CorMedix Therapeutics, stating that Nexus Pharmaceuticals infringed on patents covering MINOCIN for Injection. This decision prevents Nexus from marketing its generic minocycline product until the patents expir

Tone
Positive 72/100
Event
Market update
Published
09 Jun 2026 13:38
Source
Investing.com UK
Investing.com South Africa Direct company coverage

Federal appeals court upholds CorMedix patent win over Nexus By Investing.com

A federal appeals court has affirmed CorMedix Therapeutics' patent victory against Nexus Pharmaceuticals regarding MINOCIN for Injection. The ruling upholds a lower court's decision that Nexus infringed on CorMedix's patents, leading to a permanent injunction preventing Nexus fro

Tone
Positive 72/100
Event
Market update
Published
09 Jun 2026 02:09
Source
Investing.com South Africa
Stock Titan Direct company coverage

Court blocks generic rival to hospital antibiotic Minocin, backs CorMedix

The U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling that upholds CorMedix Therapeutics' (Nasdaq: CRMD) patents for MINOCIN® for Injection. The decision also found Nexus Pharmaceuticals' generic minocycline infringing and maintained a permanent injunction

Tone
Positive 72/100
Event
Market update
Published
08 Jun 2026 12:40
Source
Stock Titan
Stock Titan Direct company coverage

Appeals court upholds CorMedix (NASDAQ: CRMD) MINOCIN® patents and injunction

The U.S. Court of Appeals for the Federal Circuit has affirmed a lower court's judgment that Nexus Pharmaceuticals' generic minocycline product infringes two of CorMedix's MINOCIN® for Injection patents. The court also upheld a permanent injunction preventing Nexus from marketing

Tone
Positive 74/100
Event
Market update
Published
08 Jun 2026 12:40
Source
Stock Titan
Kalkine Media Direct company coverage

Can CorMedix Turn Launch Execution Into Momentum?

CorMedix (CRMD) is a specialty pharmaceutical company focused on infection prevention for hemodialysis patients using central venous catheters. The article highlights that its success hinges on effective launch execution, securing reimbursement access, ensuring manufacturing supp

Tone
Positive 62/100
Event
Market update
Published
06 Jun 2026 08:39
Source
Kalkine Media
Stocktwits Direct company coverage

Why Did CRMD Stock Tumble Over 11% Today?

CorMedix Inc.'s (CRMD) stock tumbled over 11% today despite a 312% year-on-year jump in revenue for Q4 2025, reaching $128.6 million largely due to DefenCath sales and the Melinta acquisition. The decline is attributed to an earnings per share (EPS) of $0.16, which significantly

Tone
Negative 39/100
Event
Deals and strategy
Published
05 Jun 2026 12:10
Source
Stocktwits
TradingView Direct company coverage

CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets

CorMedix Therapeutics (CRMD) is a diversified specialty pharma business experiencing strong growth. This growth is attributed to its robust product portfolio, the successful launch of DefenCath, and the expansion of its pipeline, including label extensions for REZZAYO and new opp

Tone
Positive 90/100
Event
Market update
Published
23 May 2026 06:10
Source
TradingView
MarketBeat Direct company coverage

UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD

UBS Group AG significantly reduced its stake in CorMedix Inc. by selling 454,873 shares, cutting its holdings by 41.7% in the fourth quarter. Despite this, CorMedix reported strong quarterly earnings, beating analyst estimates with $0.43 EPS and 226.1% year-over-year revenue grow

Tone
Positive 63/100
Event
Earnings
Published
19 May 2026 10:40
Source
MarketBeat
MSN Direct company coverage

CRMD Q1 earnings beat on DefenCath momentum, guidance raised

CorMedix (CRMD) reported better-than-expected Q1 earnings, driven by strong sales of DefenCath. The company's net product sales reached $8.7 million, surpassing analyst estimates, prompting an upward revision of its full-year 2026 revenue guidance to $33-38 million. This positive

Tone
Positive 77/100
Event
Earnings
Published
18 May 2026 16:39
Source
MSN
Seeking Alpha Direct company coverage

CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD)

CorMedix remains a "Sell" despite its Q1 outperformance, which is considered unsustainable due to non-recurring revenue and anticipated reimbursement challenges for DefenCath. The company faces an 80% sequential revenue decline for DefenCath post-TDAPA, and management's reaffirma

Tone
Negative 29/100
Event
Earnings
Published
18 May 2026 14:38
Source
Seeking Alpha
MarketBeat Direct company coverage

HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD)

HC Wainwright has increased its Q2 2026 EPS estimate for CorMedix to $0.26 from $0.21, maintaining a "Buy" rating and a $13 price target. This upward revision follows CorMedix's strong Q1 performance, where the company surpassed analyst expectations with $0.43 EPS and a revenue i

Tone
Positive 75/100
Event
Earnings
Published
18 May 2026 05:38
Source
MarketBeat
Simply Wall Street Direct company coverage

The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results

CorMedix (CRMD) reported strong Q1 2026 results with US$127.43 million in revenue and US$38.6 million in net income, leading to a raised full-year 2026 net revenue guidance of US$325 million to US$345 million. This positive financial update, combined with favorable Phase III resu

Tone
Positive 75/100
Event
Earnings
Published
17 May 2026 00:39
Source
Simply Wall Street
TradingView Direct company coverage

CorMedix Inc reports results for the quarter ended March 31 - Earnings Summary

CorMedix Inc has reported its earnings summary for the quarter that concluded on March 31. This brief report, provided by Refinitiv, gives investors and interested parties an overview of the company's financial performance during that period. Additional details may require loggin

Tone
Neutral 50/100
Event
Earnings
Published
15 May 2026 20:09
Source
TradingView
Stock Titan Direct company coverage

Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership

Deep Track-affiliated entities have filed a Schedule 13G/A with the SEC, disclosing a 7.94% beneficial ownership in CorMedix Inc. (CRMD), totaling 6,274,076 shares. The filing indicates shared voting and dispositive power among Deep Track Capital, LP, Deep Track Biotechnology Mas

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 12:09
Source
Stock Titan